Medicinal cannabis approvals in Australian children and young people, 2016-2024: a national analysis of Therapeutic Goods Administration data by age, indication and cannabinoid category

STRENGTHS AND LIMITATIONS OF THIS STUDY

  • This study used a large, de-identified national regulatory dataset comprising 52 419 approved Special Access Scheme Category B (SAS-B) applications for medicinal cannabis among children and young people aged 25 years or younger over more than 8 years; the supplied data did not contain names or reliable patient identifiers.

  • The application-level data enabled detailed characterisation of approvals by age, sex, indication, cannabinoid product category, formulation, duration and practitioner characteristics, using a prespecified Statistical Analysis Plan and systematic data-cleaning procedures.

  • SAS-B data obtained through Freedom of Information provided greater granularity than publicly available Therapeutic Goods Administration (TGA) dashboard data, including detailed information on practitioner type, prescriber specialty and jurisdiction, together with TGA-assigned Product Profile classifications providing more explicit information on THC classification.

  • The analysis was restricted to SAS-B approvals and did not capture access through the Authorised Prescriber…
    This post was originally published on https://bmjopen.bmj.com